ASSOCIATION OF ONCOLOGICAL RESPONSE BETWEEN THE FIRST-LINE CHEMOTHERAPY AND SUBSEQUENT IMMUNE CHECKPOINT INHIBITORS THERAPY IN PATIENTS WITH UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA Article Ozaki K., Hamaya T., Okita K., Hashimoto Y., Ohyama C., Hatakeyama S. International Journal of Urology. John Wiley & Sons. 2021.
